Previous genetic studies have examined the association of aspirin, NSAIDs, or both with colorectal cancer according to a limited number of
candidate genes or pathways.6 - 10 Thus, to comprehensively identify common genetic markers that characterize individuals who may obtain differential benefit from aspirin and NSAIDs, we conducted a
discovery - based, genome - wide analysis of
gene × environment interactions between regular use of aspirin, NSAIDs, or both and single - nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer.
Their contributions to the yeast community include physical mapping methods, synthetic lethality screen approaches for identifying cross-species
candidate genes as potential cancer drug targets, and a widely used set of vectors and yeast host strains that have been instrumental in work that has led to countless
discoveries in recent decades.
The analysis of chromosomal inheritance patterns indicated a single functional and positional
candidate gene and led to the
discovery of the COLQ c. 1010T > C mutation; however, our approach does not exclude the possibility that another mutation exists in a novel CMS
gene.